Brief: Biosenic Puts Phase IIb ALLOB Trial On Hold

Biosenic SA

19/06/2023 06:05

June 19 (Reuters) - Bone Therapeutics SA  BIOS.BR :
    * PUTS PHASE IIB ALLOB TRIAL ON HOLD
    * PRIOR EFFICACY UNMATCHED BUT EXCELLENT SAFETY PROFILE
CONFIRMED,
TIMING OF ALLOB ADMINISTRATION FOR OPTIMAL BONE REPAIR TO BE
REEVALUATED
    * ANNOUNCES DECISION TO SUSPEND ITS INTERVENTIONAL TRIAL ON
FRACTURE HEALING, USING EX-BONE-THERAPEUTICS LEAD PRODUCT, ALLOB
    * DECISION FOLLOWS NEGATIVE RESULTS OBTAINED FOR PRIMARY
ENDPOINT
IN EXPLORATORY PHASE IIB TRIAL (ALLOB IIB), WHICH FOCUSED ON
SAFETY AND TREATMENT TIMING EFFICACY
    * BIOSENIC'S CLINICAL ACTIVITIES WILL NOW FOCUS ON ITS PHASE
III
CGVHD TRIAL WITH ORAL ARSENIC TRIOXIDE (OATO)

Source text for Eikon:  ID:nGNE54s17s 
Further company coverage:  BIOS.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))